216008-35-4

Upstream product

• 100-52-7 benzaldehyde 
• 141-43-5 ethanolamine 
• 27996-87-8 2-fluoro-5-nitrobenzaldehye 

Downstream Products

• 1022952-28-8 ethyl-carbamic acid 2-[3-ethyl-1-(2-fluoro-5-nitro-benzyl)-ureido]ethyl ester 
• 669772-29-6 1-(tert-butoxycarbonyl)-5-[(2S)-2-[[2-(tert-butyldiphenylsilanyloxy)ethyl]-(2-fluoro-5-nitrobenzyl)carbamoyl]-2-(9H-fluoren-9-ylmethoxycarbonylamino)ethyl]imidazole 
• 669772-27-4 [2-(tert-butyldiphenylsilanyloxy)ethyl]-(2-fluoro-5-nitrobenzyl)amine 

Relevant academic research and scientific papers

FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS

The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

A selective AT2 receptor ligand with a gamma-turn-like mimetic replacing the amino acid residues 4-5 of angiotensin II.

Three angiotensin II (Ang II) analogues encompassing a benzodiazepine-based gamma-turn-like scaffold have been synthesized. Evaluation of the compounds in a radioligand binding assay showed that they had no affinity to the rat liver AT(1) receptor. Howeve

Amidine derivatives as inhibitors of nitric oxide synthase

There are provided novel compounds of formula (I) wherein R1represents a 2-thienyl or 3-thienyl ring and R2represents hydrogen or C 1 to 4 alkyl and optical isomers and racemates thereof and pharmaceutically acceptable salts thereof;